相似文献
1
Rituximab in rheumatic diseases.
Joint Bone Spine. 2007 Jan;74(1):4-6. doi: 10.1016/j.jbspin.2006.08.002. Epub 2006 Nov 13.
2
[Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 5. B cell targeting biologics for rheumatic diseases].
Nihon Naika Gakkai Zasshi. 2011 Oct 10;100(10):2991-7. doi: 10.2169/naika.100.2991.
3
Rituximab: therapeutic benefit! Vitamin R?
Semin Hematol. 2010 Apr;47(2):105-6. doi: 10.1053/j.seminhematol.2010.02.003.
4
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii55-9. doi: 10.1136/ard.62.suppl_2.ii55.
5
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885.
6
[Anti-CD20 antibody therapy for inflammatory immune diseases].
Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1801-6. doi: 10.2169/naika.95.1801.
7
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852.
8
CD20-targeted therapy: the next generation of antibodies.
Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007.
9
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.
10
B cells as therapeutic targets for rheumatic diseases.
Curr Opin Rheumatol. 2004 May;16(3):180-5. doi: 10.1097/00002281-200405000-00003.
Zotero 插件